207 related articles for article (PubMed ID: 24350712)
1. Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide.
Chowdhury G; Shibata N; Yamazaki H; Guengerich FP
Chem Res Toxicol; 2014 Jan; 27(1):147-56. PubMed ID: 24350712
[TBL] [Abstract][Full Text] [Related]
2. Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate.
Chowdhury G; Murayama N; Okada Y; Uno Y; Shimizu M; Shibata N; Guengerich FP; Yamazaki H
Chem Res Toxicol; 2010 Jun; 23(6):1018-24. PubMed ID: 20443640
[TBL] [Abstract][Full Text] [Related]
3. Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs.
Mancy A; Antignac M; Minoletti C; Dijols S; Mouries V; Duong NT; Battioni P; Dansette PM; Mansuy D
Biochemistry; 1999 Oct; 38(43):14264-70. PubMed ID: 10572000
[TBL] [Abstract][Full Text] [Related]
4. Species Specificity and Selection of Models for Drug Oxidations Mediated by Polymorphic Human Enzymes.
Yamazaki H; Shimizu M
Drug Metab Dispos; 2023 Jan; 51(1):123-129. PubMed ID: 35772770
[TBL] [Abstract][Full Text] [Related]
5. Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity.
Murayama N; Kazuki Y; Satoh D; Arata K; Harada T; Shibata N; Guengerich FP; Yamazaki H
J Toxicol Sci; 2017; 42(3):343-348. PubMed ID: 28496040
[TBL] [Abstract][Full Text] [Related]
6. The Dihydroxy Metabolite of the Teratogen Thalidomide Causes Oxidative DNA Damage.
Wani TH; Chakrabarty A; Shibata N; Yamazaki H; Guengerich FP; Chowdhury G
Chem Res Toxicol; 2017 Aug; 30(8):1622-1628. PubMed ID: 28745489
[TBL] [Abstract][Full Text] [Related]
7. Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites.
Marill J; Cresteil T; Lanotte M; Chabot GG
Mol Pharmacol; 2000 Dec; 58(6):1341-8. PubMed ID: 11093772
[TBL] [Abstract][Full Text] [Related]
8. Metabolic profiles of pomalidomide in human plasma simulated with pharmacokinetic data in control and humanized-liver mice.
Shimizu M; Suemizu H; Mitsui M; Shibata N; Guengerich FP; Yamazaki H
Xenobiotica; 2017 Oct; 47(10):844-848. PubMed ID: 27852146
[TBL] [Abstract][Full Text] [Related]
9. Hydroxymethylvinyl ketone: a reactive Michael acceptor formed by the oxidation of 3-butene-1,2-diol by cDNA-expressed human cytochrome P450s and mouse, rat, and human liver microsomes.
Krause RJ; Kemper RA; Elfarra AA
Chem Res Toxicol; 2001 Dec; 14(12):1590-5. PubMed ID: 11743741
[TBL] [Abstract][Full Text] [Related]
10. In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-Hydroxythalidomide in humanized TK-NOG mice.
Yamazaki H; Suemizu H; Shimizu M; Igaya S; Shibata N; Nakamura M; Chowdhury G; Guengerich FP
Chem Res Toxicol; 2012 Feb; 25(2):274-6. PubMed ID: 22268628
[TBL] [Abstract][Full Text] [Related]
11. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac.
Tang W; Stearns RA; Wang RW; Chiu SH; Baillie TA
Chem Res Toxicol; 1999 Feb; 12(2):192-9. PubMed ID: 10027798
[TBL] [Abstract][Full Text] [Related]
12. Contribution of human cytochrome P450 to benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol metabolism, as predicted from heterologous expression in yeast.
Gautier JC; Lecoeur S; Cosme J; Perret A; Urban P; Beaune P; Pompon D
Pharmacogenetics; 1996 Dec; 6(6):489-99. PubMed ID: 9014198
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Protein Binding of 5-Hydroxythalidomide Bioactivated in Humanized Mice with Human P450 3A-Chromosome or Hepatocytes by Two-Dimensional Electrophoresis/Accelerator Mass Spectrometry.
Yamazaki H; Suemizu H; Kazuki Y; Oofusa K; Kuribayashi S; Shimizu M; Ninomiya S; Horie T; Shibata N; Guengerich FP
Chem Res Toxicol; 2016 Aug; 29(8):1279-81. PubMed ID: 27464947
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP 2C18.
Minoletti C; Dijols S; Dansette PM; Mansuy D
Biochemistry; 1999 Jun; 38(24):7828-36. PubMed ID: 10387023
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation.
Chen Q; Ngui JS; Doss GA; Wang RW; Cai X; DiNinno FP; Blizzard TA; Hammond ML; Stearns RA; Evans DC; Baillie TA; Tang W
Chem Res Toxicol; 2002 Jul; 15(7):907-14. PubMed ID: 12119000
[TBL] [Abstract][Full Text] [Related]
16. Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4.
Komatsu T; Yamazaki H; Asahi S; Gillam EM; Guengerich FP; Nakajima M; Yokoi T
Drug Metab Dispos; 2000 Nov; 28(11):1361-8. PubMed ID: 11038165
[TBL] [Abstract][Full Text] [Related]
17. P450 2C18 catalyzes the metabolic bioactivation of phenytoin.
Kinobe RT; Parkinson OT; Mitchell DJ; Gillam EM
Chem Res Toxicol; 2005 Dec; 18(12):1868-75. PubMed ID: 16359177
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide metabolism by the CYP2C subfamily.
Ando Y; Fuse E; Figg WD
Clin Cancer Res; 2002 Jun; 8(6):1964-73. PubMed ID: 12060642
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics.
Patten CJ; Thomas PE; Guy RL; Lee M; Gonzalez FJ; Guengerich FP; Yang CS
Chem Res Toxicol; 1993; 6(4):511-8. PubMed ID: 8374050
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450 2A6 and other human P450 enzymes in the oxidation of flavone and flavanone.
Kakimoto K; Murayama N; Takenaka S; Nagayoshi H; Lim YR; Kim V; Kim D; Yamazaki H; Komori M; Guengerich FP; Shimada T
Xenobiotica; 2019 Feb; 49(2):131-142. PubMed ID: 29310511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
